1.
Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer
Pathologic features of prostate cancer found at population-based screening with a four-year interval
Nation-wide breast cancer screening in the Netherlands: Support for breast-cancer mortality reduction
Interval cancers in the Dutch breast cancer screening programme